Thomas P. Laughren, MD

Commentary

Increasing Schizophrenia Placebo Responses

March 3, 2020

Read commentary on the possible reasons why placebo response rates in clinical trials for schizophrenia are increasing.

Thomas P. Laughren

Review Article

Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration

March 15, 2014

Silvana Borges, Yeh-Fong Chen, Thomas P. Laughren, et al

Article

Female Reproductive Life Cycle and Hormones: Methodology to Improve Clinical Trials

October 15, 2013

Marlene P. Freeman, Rosemary Walker, Thomas P. Laughren, et al

Original Research

CYP2D6 Genotype Information to Guide Pimozide Treatment in Adult and Pediatric Patients: Basis for the US Food and Drug Administration's New Dosing Recommendations

September 15, 2012

Hobart L. Rogers, Atul Bhattaram, Issam Zineh, et al

Review Article

Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration

May 15, 2012

Ni A. Khin, Yeh-Fong Chen, Yang Yang, et al

Letter to the Editor

Reply to Failure Rate and "Professional Subjects" in Clinical Trials of Major Depressive Disorder

September 15, 2011

Ni A. Khin, Yeh-Fong Chen, Yang Yang, et al

Original Research

Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New Antidepressant

September 15, 2011

Thomas P. Laughren, Jogarao Gobburu, Robert J. Temple, et al

Original Research

Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

April 15, 2011

Ni A. Khin, Yeh-Fong Chen, Yang Yang, et al

NCDEU Festschrift

What's Next After 50 Years of Psychiatric Drug Development: An FDA Perspective

September 15, 2010

Thomas P. Laughren

Increasing Schizophrenia Placebo Responses

Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration

Female Reproductive Life Cycle and Hormones: Methodology to Improve Clinical Trials

CYP2D6 Genotype Information to Guide Pimozide Treatment in Adult and Pediatric Patients: Basis for the US Food and Drug Administration's New Dosing Recommendations

Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration

Reply to Failure Rate and "Professional Subjects" in Clinical Trials of Major Depressive Disorder

Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New Antidepressant

Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

What's Next After 50 Years of Psychiatric Drug Development: An FDA Perspective

ELSEWHERE:

FOLLOW US:

Thomas P. Laughren, MD

Increasing Schizophrenia Placebo Responses

Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration

Female Reproductive Life Cycle and Hormones: Methodology to Improve Clinical Trials

CYP2D6 Genotype Information to Guide Pimozide Treatment in Adult and Pediatric Patients: Basis for the US Food and Drug Administration's New Dosing Recommendations

Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration

Reply to Failure Rate and "Professional Subjects" in Clinical Trials of Major Depressive Disorder

Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New Antidepressant

Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

What's Next After 50 Years of Psychiatric Drug Development: An FDA Perspective

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles